You Lv1†Yan-Ling Jin1†
Ze Zhou2†
Jia-Bao Liao2Zhu-Quan Zhang1Lin-Yu Tang1
Xue-Hua Xie2
Si Wang3*Meng-Xue Jin4*Hong-Yi Liu2*- 1College of Basic Medical Sciences, Yunnan University of Chinese Medicine, Kunming, Yunnan, China
- 2The First Clinical School of Medicine, Yunnan University of Chinese Medicine, Kunming, Yunnan, China
- 3The Second Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, Yunnan, China
- 4The Third Clinical Medical College of Yunnan University of Chinese Medicine, Kunming, Yunnan, China
Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), has an important pathogenesis that lies in the self-amplifying inflammatory circuit formed by bidirectional interactions between dendritic cells (DCs) and T follicular helper (TFH) cells. This review elucidates that specific mature DC subsets in the intestinal inflammatory microenvironment drive TFH cell differentiation through synergistic co-stimulatory signals (CD80/CD86-CD28, OX40L-OX40) and cytokine networks (IL-12/STAT4/BCL-6, TGF-β/c-Maf/CXCR5); conversely, TFH-derived Lymphotoxin alpha 1 beta 2 (LTα1β2) activates stromal cell LTβR/NF-κB signaling pathway, inducing chemokine (CXCL13, CCL19, CCL21) production, thereby recruiting CCR7+ DC and CXCR5+ lymphocytes to form structural lymphoid clusters. Within these clusters, sustained DC-TFH cell interactions enhance TFH pathological effector functions (e.g., excessive IL-21 secretion), promote Th1/Th17 differentiation and weaken regulatory T cell inhibitory capacity, ultimately causing barrier destruction and tissue damage. Notably, while this pathogenic axis is active in both CD and UC, its cellular dynamics and microenvironment may exhibit disease-subtype distinctions. Current therapeutic strategies targeting this axis—including JAK inhibitors (e.g., upadacitinib), cytokine biologics (e.g., ustekinumab) and integrin blockers (e.g., vedolizumab)—achieve efficacy by interfering with DC-dependent TFH differentiation or TFH-mediated DC aggregation. Emerging evidence indicates traditional Chinese medicine active components (e.g., ginsenoside Rh2, curcumin) may intervene in this interaction through multi-pathway immunoregulation. However, utilizing single-cell and spatial transcriptomics to analyze spatial characteristics and disease-subtype-specific profiles of DC-TFH cell interactions remains key to developing next-generation therapies. While this axis provides a novel perspective for understanding immune dysregulation in IBD, its temporal role in disease initiation, crosstalk with other immune pathways, and translation from animal models to human disease remain challenges and future directions for the field.
1 Introduction
Inflammatory bowel disease (IBD) is a non-infectious, chronic, gastrointestinal inflammatory disorder characterized by alternating periods of relapse and remission, heterogeneous clinical manifestations, and the presence of one or more extraintestinal manifestations (1). IBD mainly includes two subtypes—Crohn’s disease (CD) and ulcerative colitis (UC) (2)—While both diseases predominantly affect the gastrointestinal tract, they differ in the specific sites and extent of involvement. For instance, CD can involve any part of the gastrointestinal tract from the mouth to the anus, while UC is mostly confined to the colon and rectum (3, 4). Beyond anatomical distribution, CD and UC are also characterized by distinct immunopathological features: CD is typically associated with a T helper 1 (Th1)/Th17-driven transmural inflammation, whereas UC often involves a more superficial, mucosal inflammation with a prominent Th2 component. Recurrent episodes of the disease can lead to complications such as perforation, fistula, toxic megacolon, and cancer, which can greatly affect the professional and personal life of patients. A meta-analysis showed that the incidence of colon cancer progressively increases with disease duration, rising from 1.6% at 10 years to 8.3% at 20 years, and further to 18.4% at 30 years (5), thereby imposing a substantial global public health burden.
Although traditional anti-IBD drugs such as 5-aminosalicylic acid, azathioprine, methotrexate, and corticosteroids have proven effective in the treatment of the disease, the acceleration of globalization and changes in dietary patterns have inevitably led to a rapid increase in the global prevalence of IBD. It is estimated that over 6.8 million people are affected by this condition worldwide. The geographical pattern of IBD incidence has gradually expanded from an initial predominance in Western countries to encompass developing countries in Asia, Eastern Europe, and Africa. For instance, in India, the incidence rate of IBD is reported at 9.31 per 100, 000 person-years (6). The main reason for the spread of IBD is the incomplete understanding of its driving factors. However, it is well established that the onset of IBD results from complex interactions between genetic and environmental factors, including diet, with gut dysbiosis, intestinal barrier damage, and abnormal immune responses all making significant contributions (7, 8). Specifically, inflammation in IBD is initially triggered by the innate immune response, primarily in response to intestinal barrier damage. Gut dysbiosis has been confirmed to be a key link in amplifying and maintaining the intestinal inflammatory response, further exacerbating intestinal barrier disruption (9–11) This process provides co-stimulatory signals for subsequent adaptive immune activation, ultimately promoting disease progression (11). Consequently, a comprehensive investigation into immune cell-targeting strategies holds promise for the dynamic monitoring of IBD as well as for improving disease outcomes (11–14).
Over recent years, the dynamic interaction between dendritic cells (DCs) and T follicular helper (TFH) cells has received increasing attention for its central role in driving IBD pathogenesis. This interaction constitutes a key pro-inflammatory positive feedback loop: in mouse mesenteric lymph node studies, specific mature DC subsets can effectively induce the differentiation of pro-inflammatory, dysfunctional TFH cells (15). Notably, this DC-TFH axis is active in both CD and UC, though its cellular composition and microenvironmental triggers may differ between the two subtypes. Meanwhile, these abnormally activated TFH cells, which express C-X-C motif chemokine receptor 5 (CXCR5), promote the recruitment and local activation of specific DC subsets or their precursors to sites of inflammation. They do so by participating in the shaping of the microenvironment of gut-associated lymphoid tissues, such as germinal centers (GCs), partly by promoting the production of chemokines such as C-X-C motif chemokine 13 (CXCL13) (16). This bidirectional interaction leads to the establishment of a close DC-TFH cell interaction network in the follicle-associated regions of tertiary lymphoid structures formed in secondary lymphoid organs, such as mesenteric lymph nodes, or at the sites of intestinal inflammation.
Within this network, DCs continuously provide excessive antigen presentation and co-stimulatory signals, such as CD80/CD86 and inducible co-stimulator ligand (ICOSL). These not only maintain and expand the population of dysfunctional TFH cells but also significantly enhance their effector functions, including the high-level secretion of pro-inflammatory cytokines such as interleukin-21 (IL-21) (15, 17–19), and directly exacerbate local inflammatory responses. The inflammatory microenvironment maintained by DC-TFH cell interactions and the effector factors produced by TFH cells, especially IL-21, further drive the differentiation, activation, and expansion of various pro-inflammatory effector T-cell subsets (such as Th1 and Th17 cells) (20, 21). These activated effector T cells migrate to the intestinal lamina propria, where they directly mediate epithelial barrier disruption and intestinal tissue damage, which jointly promote IBD pathology.
Accordingly, in this review, we discuss the key roles of DCs and TFH cells in the occurrence and development of IBD and delve into the core pro-inflammatory mechanisms established.
2 The function of DCs is related to their state
As early as 1973, Ralph Steinman and Zanvil Cohn made the initial discovery of a rare type of cell in the mouse spleen. These cells had stellate or dendritic protrusions on their surface, from which DCs derive their name. Simultaneously, the phagocytic function of DCs was also reported for the first time (22), marking the formal introduction of DCs into the scientific research landscape. In 1978, Steinman’s group further confirmed that the immune response of lymphocytes is mainly dependent on DCs (23), and, in 2011, he was awarded the Nobel Prize in Physiology or Medicine for his contribution to the discovery of DCs and their role in adaptive immunity. Since then, an increasing number of studies have confirmed that DCs can recognize, capture, and phagocytose pathogens, breaking them down into small molecular fragments, which DCs then present on their cell surface. DCs then transport these fragments to lymphocyte-rich areas, where they present antigenic information to T cells, thereby activating adaptive immunity and directing them to effectively eliminate foreign invaders. Given these findings, in 2010, DC cell therapy was officially approved for cancer treatment, underscoring that the discovery of DCs not only changed the understanding of the mechanism underlying immune system function but also promoted the development of immunotherapy (24) (Figure 1).
Figure 1. The historical development of DCs. The initial discovery of DCs, characterized by their stellate or dendritic protrusions, was made in the mouse spleen in 1973, with their phagocytic function reported simultaneously. In 1978, it was confirmed that the immune response of lymphocytes is mainly dependent on DCs. The discovery of DCs and their role in adaptive immunity was recognized with the Nobel Prize in 2011. DCs recognize, capture, and phagocytose pathogens, presenting antigenic information to T cells to activate adaptive immunity. In 2010, DC cell therapy was officially approved for cancer treatment.
DCs exhibit marked heterogeneity and can be subdivided into distinct subsets according to their ontogeny, surface markers and functional specialisation. Each subset performs dedicated/specialized functions in intestinal immune surveillance and response. As illustrated in Table 1, the major DC compartments comprise conventional dendritic cells (cDCs, further separable into cDC1 and cDC2) (25), plasmacytoid dendritic cells (pDCs), monocyte-derived dendritic cells (Mo-DCs) and mature DCs enriched in immunoregulatory molecules (mregDC). Each subset displays a unique repertoire of surface receptors and performs dedicated tasks in antigen capture, processing, presentation and cytokine secretion, thereby tailoring specific immune responses in different tissue environments. The functional characteristics of the different subtypes are determined by their developmental pathway. However, the function of DCs is mainly related to their maturation state. Immature DCs do not possess antigen-presenting ability but can migrate to almost all lymphoid tissues throughout the body. They internalize antigens through phagocytosis and pinocytosis and exhibit an immune-tolerant phenotype toward substances recognized as “self” antigens (26). In this immature state, DCs play a role in inhibiting T-cell activity and contribute to the regulation of immune tolerance, acting as “phagocytic cells” with immune-tolerant regulatory effects. However, when they recognize “foreign” pathogens, DCs bind pathogen-associated molecular patterns (PAMPs) through pattern recognition receptors (PRRs) on their surface, and begin to differentiate and mature. They then express high levels of both co-stimulatory and MHC molecules. Meanwhile, they process and synthesize the ingested antigens into antigenic peptides, load them onto MHC molecules, migrate from peripheral tissues into adjacent secondary lymphoid tissues, and present the antigens on the MHC molecules to T cells. After specific binding, they activate adaptive immunity and become “bridge cells” linking innate and adaptive immunity (26, 27) (Figure 2).
Table 1. Major dendritic cell subsets in intestinal immunity.
Figure 2. The functional transition of DCs from an immature to a mature state. Immature DCs act as “phagocytic cells” with immune-tolerant regulatory effects, internalizing antigens and inhibiting T-cell activity. Upon encountering pathogens, DCs mature, express high levels of co-stimulatory and MHC molecules, process antigens, and present them to T cells, thereby becoming “bridge cells” that activate adaptive immunity.
2.1 Immature DCs have phagocytic and immune tolerance regulatory functions
Under physiological conditions, DCs exist in a dynamic immature state (28). Immature DCs have a smooth surface and exhibit elevated expression of phagocytosis-related receptors, including Toll-like receptors (TLRs), C-type lectin receptors (CLRs), and scavenger receptors (SRs) (29–32). These receptors contribute to the recognition of “self” antigens such as nucleic acids (DNA/RNA) and histones released after necrosis or apoptosis. For example, TLR9 can recognize unmethylated CpG DNA exposed after cell damage (33), while TLR7 and TLR8 primarily recognize single-stranded RNA (33, 34). C-type lectin receptors mediate glycan recognition on antigens (35), and scavenger receptors often help recognize oxidatively modified ligands under oxidative stress conditions (36). Subsequently, these phagocytosis-related receptors bind to “self” antigens, forming phagocytic cups that continuously close, encapsulating and internalizing the antigens within membrane-bound vesicles called phagosomes. The phagosomes fuse with lysosomes to process the antigens, which are then loaded onto MHC molecules on the surface of DC cells (32). Moreover, as apoptotic cells lack the necessary stimulating signals to activate co-stimulatory molecules and MHC molecules on the surface of immature DCs, the initiation of T cell-mediated adaptive immunity is transiently impeded (37).
When processing “self” antigens, immature DCs concurrently guide T cells to respond to “self” antigens in an immunosuppressive manner by secreting immunosuppressive factors such as IL-10 (38) and transforming growth factor-beta (TGF-β). Thus, in addition to phagocytosis, the regulation of immune tolerance represents another key function of immature DCs (39–41). After binding to receptors on the surface of T cells, IL-10 can activate Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), leading to the phosphorylation of signal transducer and activator of transcription 1 (STAT1) and STAT3, thereby inhibiting the activation of Th1 cells and reducing the production of pro-inflammatory cytokines (42–44). Furthermore, under the regulation of IL-10, the expression of co-stimulatory molecule CD80 and MHC on the surface of DCs is significantly reduced (45, 46). Additionally, IL-10 inhibits tyrosine phosphorylation in the T cell-specific surface glycoprotein CD28 and prevents the binding of phosphatidylinositol 3-kinase (PI3K) p85, thereby blocking the CD28 signaling pathway (47). As a result, T-cell polarization is inhibited due to the lack of co-stimulatory signals. TGF-β mainly regulates the proliferation and activation of T cells by specifically binding to TGF-β receptor II (TGF-βRII), leading to the recruitment of TGF-β receptor I (TGF-βRI) and the formation of a signaling complex composed of TGF-β/TGF-βRI/TGF-βRII. Once this complex has formed, TGF-βRII, which possesses intrinsic kinase activity, phosphorylates and activates TGF-βRI, leading to its dissociation from the signaling inhibitor FK506-binding protein 1A (FKBP1A). Activated TGF-βRI subsequently interacts with receptor-regulated small mothers against decapentaplegic (SMAD) proteins (R-SMADs), which are presented to TGF-βRI, and then phosphorylated and activated under the mediation of the adaptor protein SARA. Phosphorylated R-SMADs subsequently combine with SMAD4, forming a heterotrimeric complex (48). This complex translocates to the nucleus where it binds to specific DNA sequences and interacts with various transcription factors and co-regulators. Through this transcriptional regulation, the SMAD complex upregulates genes encoding cell cycle inhibitors (e.g., p15, p21), which arrest T cell proliferation, and promotes the expression of genes involved in the differentiation and function of regulatory T cells (Tregs). TGF-β signaling also modulates T cell receptor signaling thresholds and inhibits pro-inflammatory cytokine production, collectively suppressing T cell activation and proliferation, and enforcing immune tolerance (49, 50).
2.2 Following stimulation by “foreign” pathogens, DCs differentiate and mature, and their antigen-presenting ability is enhanced
When immature DCs recognize PAMPs of “foreign” pathogens such as bacteria and viruses through their surface PRRs, they initiate a maturation and differentiation program and activate a downstream signaling network (51). For instance, once TLR4 specifically recognizes lipopolysaccharide (LPS) from Gram-negative bacteria, it recruits interleukin-1 receptor-associated kinase 1/4 (IRAK1/4) through the myeloid differentiation factor 88 (MyD88) adaptor protein. This complex, in turn, mediates the polymerization and ubiquitination of tumor necrosis factor receptor-associated factor 6 (TRAF6), ultimately leading to the activation of transforming growth factor β-activated kinase 1 (TAK1). Signaling then diverges into two key pathways, involving either the secretion of inflammatory cytokines through the nuclear factor-kappa B (NF-κB) pathway or the regulation of cell proliferation through the mitogen-activated protein kinase (MAPK) pathway (52, 53). Notably, NF-κB, a core regulator of DC maturation, can directly bind to the promoter regions of genes encoding MHC and co-stimulatory molecules such as CD80/CD86 (54, 55). The MAPK pathway, meanwhile, indirectly enhances the expression of the above-mentioned immune molecules by activating transcription factors such as NF-κB and STAT proteins (56, 57). Following DC maturation, the expression of MHC molecules on the surface of these cells is significantly upregulated. MHC class I molecules present endogenous antigenic peptides, such as those derived from viruses, to CD8+ T cells, whereas MHC class II molecules present exogenous antigenic peptides, such as degradation products of bacterial proteins, to CD4+ T cells, thereby initiating specific T-cell responses (58–60).
However, effective T-cell activation strictly follows the two-signal activation principle. In addition to the first signal mediated by the MHC-antigenic peptide-TCR complex, the second signal provided by co-stimulatory molecules, such as CD80/CD86 and CD40, on the surface of DCs is also crucial for the stability of the immunological synapse and downstream signal transduction. When the TCR-CD3 complex recognizes the MHC-antigenic peptide complex (the first signal), lymphocyte-specific tyrosine kinase (Lck) phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs), leading to the recruitment and activation of ζ-chain-associated protein kinase 70 (ZAP-70), and, ultimately, the activation of the MAPK signaling cascade (61–63). Meanwhile, the binding of the co-stimulatory molecules CD80 and CD86 on DCs to CD28 on T cells (the second signal) triggers the phosphorylation of tyrosine residues in the intracellular domain of CD28, leading to the recruitment of phosphatidylinositol 3-kinase (PI3K) via its SH2 domains and, eventually, the activation of the PI3K-AKT pathway. Ultimately, the two signals are precisely coordinated in both temporal and spatial dimensions: the antigen-specific recognition—the first signal—provides the basic framework for activation, while the second signal dynamically regulates metabolic reprogramming and cell cycle progression through the PI3K-AKT pathway. Finally, through the synergistic action of the nuclear factor of activated T-cells (NFAT)/activator protein 1 (AP-1) and NF-κB transcription complexes, T cells are fully activated and antigen-specific adaptive immune responses are initiated (64, 65).
3 Adaptive immune activation initiates TFH cell differentiation and pro-inflammatory functions
TFH cells were first described in human lymphoid tissues in 1998 as CXCR5+CD4+ T cells residing within B cell follicles, although their functional identity as a distinct T helper subset remained undefined for decades (66). A major conceptual advance came in 2000, when CXCR5+ T cells were shown to migrate into follicles and deliver essential help to B cells, distinguishing them from classical Th1 and Th2 lineages. This led to the formal recognition of TFH cells as a separate effector T cell population (67).
The molecular identity of TFH cells was refined in 2005, when microarray analyses revealed a transcriptional signature unique to this subset, underscoring their specialized role in humoral immunity. Subsequent studies identified Bcl6 as the master transcription factor governing TFH differentiation, solidifying their developmental independence from other CD4+ T helper subsets (68). In 2009, the RING-type ubiquitin ligase Roquin was implicated in restraining TFH responses by destabilizing ICOS mRNA; its deficiency resulted in TFH hyperaccumulation and systemic autoimmunity, emphasizing the importance of post-transcriptional regulation in immune tolerance (69, 70).
More recently, the transcription factors Tox and Tox2 has been identified as a pioneer transcription factor that cooperates with Bcl6 to establish and maintain TFH lineage identity (71). Collectively, these findings position TFH cells as a central conduit between antigen-specific T cell priming and the generation of high-affinity, class-switched antibody responses by B cells, reinforcing the principle that adaptive immunity hinges upon the precise orchestration of T–B lymphocyte synergy (Figure 3).
Figure 3. The historical development of TFH Cells. TFH cells were first described in human lymphoid tissues in 1998. Their functional identity was established in 2000 when CXCR5+ T cells were shown to migrate into follicles and deliver essential help to B cells. Their molecular identity was refined in 2005 with the revelation of a unique transcriptional signature and the identification of BCL-6 as their master transcription factor. In 2009, the RING-type ubiquitin ligase Roquin was implicated in restraining TFH responses, and more recently, the transcription factors Tox and Tox2 were identified as a pioneer factor cooperating with BCL-6.
T-cell activation serves not only as the initiating step in the immune response but also as a key hub of the regulatory network. At the level of cellular immunity, activated CD8+ T cells specifically recognize the MHC class I molecule-antigen peptide complex on the surface of target cells through TCRs, differentiate into cytotoxic T lymphocytes (CTLs), and induce target cell apoptosis through the perforin/granzyme system and the Fas/FasL signaling pathway (72, 73). Simultaneously, CD4+ T cells recognize the MHC class II molecule-antigen peptide complex on the surface of antigen-presenting cells (APCs) and differentiate into functionally diverse T helper cell subsets. One of these subsets—TFH cells—are the core regulators of the humoral immune response due to their unique localization within GCs and their ability to support B cell functions (74–76). The TFH system primarily includes helper subsets (TFH, TPH, cTFH) and a suppressive subset (TFR), which together regulate the antibody response (Detailed classification shown in Figure 4). This functional heterogeneity is reflected in distinct TFH-lineage subsets defined by surface markers and transcriptional programs (Figure 5). Classical germinal center TFH cells (hereafter TFH) are identified as CXCR5+ICOS+PD-1+BCL-6+ and are essential for providing help to B cells (77, 78). Circulating TFH cells (cTFH; CD4+CXCR5+PD-1+) represent their peripheral counterparts and may serve as a accessible biomarker for systemic TFH activity (79). Peripheral helper T cells (TPH; CXCR5⁻PD-1+ICOS+) provide B cell help in extrafollicular regions, potentially contributing to early or ectopic antibody responses (80, 81). Crucially, the follicular regulatory T cell subset (TFR; CXCR5+FOXP3+PD-1+) functions as a key suppressive counterpart within follicles (82). In the context of IBD, an imbalance within this system is often observed. Notably, TFR cells, which are critical for constraining excessive germinal center reactions and autoantibody production, are frequently impaired in function or reduced in frequency within inflamed intestinal tissues. This loss of regulatory restraint may directly contribute to the pathological expansion and sustained activity of pro-inflammatory TFH cells, thereby exacerbating chronic inflammation (83).
Figure 4. Functional classification and defining markers of TFH-cell subsets. The TFH-cell family comprises four major subsets with distinct roles in antibody responses. Germinal center TFH cells (GC-TFH) are defined by high expression of CXCR5, ICOS, and PD-1, and depend on the transcription factor BCL-6. Circulating TFH cells (cTFH) share CXCR5 and PD-1 expression and serve as a peripheral biomarker. Peripheral helper T cells (TPH) lack CXCR5 but express PD-1 and ICOS, enabling B cell help at extrafollicular inflammatory sites. Follicular regulatory T cells (TFR) co-express the follicular homing marker CXCR5 with the regulatory master transcription factor FOXP3, alongside PD-1 and CD25, and function to suppress excessive immune responses.
Figure 5. Adaptive immune activation initiates TFH differentiation and pro-inflammatory functions. Activated CD8+ T cells differentiate into CTLs and induce target cell apoptosis. CD4+ T cells differentiate into subsets including TFH cells, which are core regulators of the humoral immune response. Following dual-signal stimulation, naive CD4+ T cells upregulate BCL-6 and acquire the CXCR5highPD-1high phenotype. Guided by the CXCR5-CXCL13 axis, TFH cells migrate to germinal centers, where via ICOS/ICOSL, CD40L-CD40, and IL-21, they drive B-cell differentiation. TFH cells also secrete IL-21 and IFN-γ, which can trigger inflammatory cascades, and their abnormal activation is associated with autoimmune diseases.
A typical feature of TFH cells is their high expression of CXCR5 (84). TFH cell differentiation follows a multi-stage, dynamically regulated process. After receiving dual-signal stimulation—TCR-MHC II/antigen peptide presented by APCs—naive CD4+ T cells initiate the differentiation program primarily via IL-6-STAT3 signaling, upregulate the expression of the key transcription factor BCL-6, transition through the precursor TFH (pre-TFH) stage and finally acquire the CXCR5highPD-1high effector phenotype (18). Importantly, follicular dendritic cells (FDCs) form a chemotactic gradient by secreting CXCL13, guiding TFH cell migration to GC regions through the CXCR5-CXCL13 axis (16, 85, 86). In the GC microenvironment, TFH cells first establish stable contacts with B cells through the inducible T-cell co-stimulator ICOS/ICOSL signaling pathway. Subsequently, through CD40L-CD40 co-stimulation and the simultaneous secretion of IL-21, they drive B-cell differentiation into plasma cells and memory B cells. This process also involves the fine regulation of intercellular synapse formation by the SLAM-associated protein (SAP) –signaling lymphocytic activation molecule (SLAM) interaction network (87–90). Sustained BCL-6 expression maintains the functional maturity of TFH cells by enforcing their transcriptional identity (84).
Meanwhile, mechanistic studies have shown that the immune regulatory function of TFH cells is bidirectional. IL-21 and interferon-gamma (IFN-γ) secreted by TFH cells can not only enhance the intensity of the GC response but also trigger local inflammatory cascades by activating the macrophage TLR4/NF-κB pathway and inducing the formation of neutrophil extracellular traps (NETs) (91). This pro-inflammatory property makes TFH cells an important hub connecting adaptive and innate immunity. Moreover, numerous studies have confirmed that the abnormal activation of TFH cells is associated with a variety of autoimmune diseases, such as rheumatoid arthritis (84, 92). DCs may be significant contributors to intestinal immune homeostasis imbalance through their regulatory effect on the TFH cell differentiation microenvironment. The interaction between the two cell types serves as a key driver of IBD pathology (15, 93) (Figure 5).
4 The interaction between DCs and TFH cells drives the development of IBD
4.1 DCs promote TFH cell differentiation
4.1.1 DCs provide co-stimulatory signals to activate transcription factors and trigger TFH cell differentiation
In IBD pathology, DCs engage in dynamic interactions with TFH cells through a network of co-stimulatory molecules, serving as the core mechanism driving abnormal intestinal immune responses. The binding of B7 family molecules (CD80/CD86) on the surface of DCs, particularly on cDC1 and cDC2 subsets (Table 1), to CD28 on naive CD4+ T cells not only enhances the phosphorylation of ITAMs within the TCR/CD3 complex through the activation of Lck/Fyn kinases but also stabilizes the binding of ZAP-70 kinase to the CD3ζ chain by inducing conformational changes at the Y315/Y319 sites of ZAP-70 kinase, thereby significantly amplifying the strength of TCR signals (94–97). This synergy lowers the response threshold of T cells to antigens to a pathological level, laying a molecular foundation for the dysregulated differentiation of TFH cells. Notably, OX40L derived from cDC2 cells (Table 1) interacts with the OX40 receptor, leading to its trimerization and the subsequent recruitment of TRAF2/3/5 adaptor proteins (98). On the one hand, this results in the activation of the canonical NF-κB pathway through the receptor-interacting protein 1 (RIP1)/inhibitor of nuclear factor kappa-B kinase (IKKα/β/γ) complex, leading to IκBα degradation and the nuclear translocation of reticuloendotheliosis viral oncogene homolog A (RelA)/nuclear factor kappa-B subunit 1 (p50). This mechanism can maintain TFH cell survival even in the absence of antigen stimulation (98–101). On the other hand, the non-canonical NF-κB2 pathway is activated through the CARD-containing MAGUK protein 1 (CARMA1)/B-cell lymphoma/leukemia 10 (BCL-10)/mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1)/protein kinase C theta (PKCθ) complex, inducing the formation of RelB/p52 heterodimers, and, consequently, prolonging NF-κB activity (102). This antigen-independent and sustained signal transduction may be a key trigger for the abnormal activation of TFH cells in IBD. Crucially, the OX40/OX40L axis exhibits unique bidirectional regulatory properties in the GC microenvironment. TFH cells promote IL-21 secretion by receiving B-cell-derived OX40L signals through OX40, while B cells achieve clonal expansion by activating the PI3K-AKT pathway through reverse signaling, forming a positive feedback loop (100, 103, 104). Tahiliani et al. (103) reported that TFH cells in OX40-deficient mice cannot support GC formation, and abnormal GC reactions in the intestinal mucosa are one of the pathological features of IBD. These GC reactions are a hallmark of CD and are also observed in a subset of UC patients, highlighting a shared but variably expressed pathological node. It is noteworthy that OX40/OX40L signaling is context-dependent in immune regulation (105). Under certain experimental conditions, it has also been reported to potentially contribute to the generation of regulatory cells (106), suggesting that its net effect in IBD may be more complex and is precisely regulated by the local microenvironment.
The regulation of TFH cell differentiation by DCs is also reflected in the precise coordination between the CXCL13-CXCR5 chemokine axis and the BCL-6 transcription network. Although activated CD4+ T cells can transiently express CXCR5, the stable expression of this receptor requires DCs to continuously secrete CXCL13 to drive T-cell migration to the T/B cell border zone (91, 107, 108). In this process, BCL-6 relieves the Blimp-1-mediated inhibition of TFH cell differentiation through dual mechanisms. On the one hand, its broad-complex, tramtrack, and bric-à-brac (BTB) domain recruits histone deacetylase 2 (HDAC2), which reduces the level of histone H3K27ac modification at the PRDM1 promoter region; on the other hand, it competitively binds to the AP-1 site through its zinc finger domain, blocking the c-Fos/c-Jun complex-mediated transcriptional activation of Th1-polarization genes, such as IFNG (109, 110). IL-21 secreted by mature TFH cells can transactivate CXCL13 expression in DCs, forming an autocrine amplification loop. This abnormal chemokine-transcription factor network may lead to the continuous accumulation of TFH cells in the intestines of patients with IBD (111). The above-described mechanisms reveal that DCs not only initiate the TFH cell differentiation program through co-stimulatory signals but also maintain the pathological activity of TFH cells by establishing a distinctive immune microenvironment that provides a structural basis for subsequent DCs to secrete cytokines such as IL-12 and TGF-β, thus further modulating TFH cell functions (Figure 6).
Figure 6. DCs provide co-stimulatory signals to activate transcription factors and trigger TFH cell differentiation. The binding of DC-derived B7 molecules (CD80/CD86) to CD28 on naive CD4+ T cells synergistically amplifies TCR signals. Concurrently, the OX40L-OX40 interaction activates both canonical and non-canonical NF-κB pathways, maintaining TFH cell survival and promoting antigen-independent activation. Furthermore, DC-secreted CXCL13 and the BCL-6 transcriptional network coordinate to stabilize CXCR5 expression and enforce TFH lineage commitment. IL-21 from mature TFH cells transactivates CXCL13 in DCs, forming an autocrine amplification loop that may lead to pathological TFH accumulation in IBD.
4.1.2 DCs initiate signal transduction and promote TFH cell differentiation by secreting cytokines
Once DCs have initiated TFH cell differentiation through co-stimulatory signals, they further secrete a range of cytokines that finely regulate the TFH cell differentiation program, constituting a key link in the progression of IBD. Following the initial activation of T cells induced by the B7-CD28 signal on the DC surface, IL-12 derived from cDC1s (Table 1) plays a key regulatory role through the IL-12Rβ2-JAK2/TYK2-STAT4 signaling axis. Specifically, the phosphorylation of STAT4 at Tyr693 induces its homodimerization and subsequent translocation to the nucleus, where it directly activates the transcription of BCL-6- and ICOS-encoding genes. Concurrently, STAT3 Ser727 phosphorylation enhances H3K4me3 histone modification in the BCL6 promoter region, thus establishing the epigenetic characteristics of pro-inflammatory TFH cells (112–117). Meanwhile, TGF-β, which is highly expressed by cDC2s and Mo-DCs in the IBD inflammatory microenvironment, directly binds to the CXCR5 promoter through the SMAD2/3-c-Maf complex, thereby upregulating its expression, and promotes TFH cell migration to the GC in a BCL-6-independent manner (118, 119). Human single-cell transcriptome analysis reveals that single-cell transcriptome analysis showed that the proportion of c-Maf+ TFH cells in the mesenteric lymph nodes of IBD patients is significantly increased relative to controls, and the CXCR5 expression level in these cells is positively correlated with disease activity index scores (120–122) This suggests that the TGF-β/SMAD pathway exacerbates local intestinal immune responses by modulating the tissue-specific localization of TFH cells. Future studies are needed to delineate whether this c-Maf+ TFH signature is equally prominent in CD and UC. In addition, IL-6 secreted by DCs is considered to be an important cytokine driving TFH cell differentiation. Studies in Il6⁻/⁻ mice show IL-6 exerts its effects by transiently activating STAT3, which induces BCL-6 expression in CD4+ T cells. IBD-related studies have demonstrated that IL-6 deficiency can lead to impaired early-stage TFH cell differentiation, while elevated BCL-6 expression can directly promote CXCR5 upregulation. These findings emphasize the importance of the IL-6/STAT3/BCL-6 axis in the abnormal differentiation of TFH cells in the context of intestinal inflammation in IBD (123) (Figure 7).
Figure 7. DCs initiate signal transduction and promote TFH cell differentiation by secreting cytokines. DC-derived IL-12 acts via the IL-12Rβ2-JAK2/TYK2-STAT4 axis to activate transcription of BCL-6 and ICOS, while STAT3 Ser727 phosphorylation enhances H3K4me3 modification at the BCL-6 promoter. TGF-β upregulates CXCR5 expression via the SMAD2/3-c-Maf complex, guiding TFH cell migration. Additionally, IL-6 transiently activates STAT3 to induce BCL-6 expression, further reinforcing the TFH differentiation program.
Notably, DC subsets exhibit differential capacities to drive TFH differentiation. cDC1 cells, through robust IL-12 secretion, preferentially promote TFH subsets with a Th1-like phenotype (sometimes termed TFH1), which may be more relevant in CD (124–126). In contrast, cDC2 cells, via OX40L and TGF-β, support classical TFH differentiation and are often enriched in UC mucosa (127). Mo-DCs, abundant in inflamed tissues, sustain TFH activity through IL-6 and IL-23 (128). Meanwhile, mregDCs may indirectly modulate TFH responses by fostering TFR cell development (129), highlighting the intricate subset-specific crosstalk within the DC–TFH axis.
In summary, DCs precisely regulate multiple signal transduction pathways (JAK-STAT, SMAD) through the secretion of cytokines such as IL-12, TGF-β, and IL-6, synergistically promoting the activation of key transcription factors (BCL-6, c-Maf) and the expression of TFH cell signature molecules (CXCR5), ultimately driving the differentiation and function of TFH cells. This has significant pathological significance for the persistent chronic inflammation and abnormal antibody responses observed in IBD.
4.2 TFH cells mediate the recruitment of mature DCs and synergistically drive the formation of DC/T-cell clusters, thus promoting IBD pathology
Furthermore, the abnormal accumulation of mature DCs mediated by TFH cells at IBD lesion sites and the formation of highly ordered “DC/CD4+ T-cell clusters” in the T cell zone (15) are also crucial in promoting IBD pathology. Such organized clusters are particularly characteristic of the transmural inflammation seen in CD, whereas in UC, immune aggregates may be more superficially localized within the mucosa, which may partially explain the differential responses of the two subtypes to therapies targeting lymphocyte recruitment. Murine experiments show that, classical GC-TFH cells (Figure 5) within the cluster exhibit high expression of lymphotoxin-alpha (LTα). Stimulated by microbial products (such as lipoteichoic acid from Gram-positive bacteria), TFH cells can express both LTα and LTβ. These molecules assemble on the cell surface to form the membrane-bound heterotrimeric ligand LTα1β2. The LTα1β2 trimer binds to the lymphotoxin beta receptor (LTβR) on DCs and stromal cells. This binding triggers the downstream signaling cascade: TRAF2 and TRAF3 recruit cIAP1/2 to the LTβR complex, leading to K63-linked ubiquitination of TRAF3 and its subsequent proteasomal degradation. Since TRAF3 constitutively inhibits NIK, its degradation allows for the stabilization and accumulation of NIK (15, 130, 131). which then activates the non-canonical NF-κB signaling pathway and initiates the transcription of specific chemokines, such as CXCL13, CCL19, and CCL21 (132, 133). These chemokines further recruit additional CXCR5+ lymphocytes (including TFH cells) and CCR7+ mature DCs, including the cDC1 and cDC2 subsets (Table 1), to the IBD lesions (134), thus exacerbating DC accumulation and promoting the expansion of DC/T-cell clusters.
T cells within the expanded DC/T-cell clusters receive significantly enhanced and prolonged antigenic signals from DCs, leading to excessive activation of CD4+ T cells and their abnormal differentiation into various pro-inflammatory effector T-cell subsets, including Th1 and Th17 cells (12), In the murine DSS model, this process is reproduced, human single-cell data similarly show expanded Th1/Th17 modules in active IBD, this is often accompanied by the inhibition of the function or differentiation of Tregs (see below). These differentiated effector T cells migrate to the intestinal lamina propria, exerting pro-inflammatory effects and directly driving IBD pathology. Notably, the differentiation of Th1 cells and their effector mechanisms are particularly critical. IL-12, secreted by DCs, binds to IL-12R and activates JAK2/TYK2-STAT4 signaling, which, in turn, induces the expression of T-box transcription factor (T-bet) (135). Human genetic studies complement these murine observations: T-bet directly drives the Th1 cell differentiation program and promotes massive IFN-γ production. IFN-γ further strengthens T-bet expression through the STAT1 phosphorylation (136), forming a positive feedback loop. Genetic studies of IBD patients (137) (involving SNP rs1551398/rs1551399, which affects T-bet binding) and functional studies (138) (involving the alleviation of IBD through IFN-γ deficiency in an animal model) both support the importance of Th1 cell responses. Activated Th1 cells secrete cytokines, such as IFN-γ and tumor necrosis factor-alpha (TNF-α), which stimulate macrophages/neutrophils, upregulate the expression of epithelial adhesion molecules (e.g., MAdCAM-1), promote immune cell infiltration, and directly or indirectly induce intestinal epithelial cell apoptosis and dysfunction, thereby disrupting the intestinal barrier (136, 138).
In addition to driving Th1 cell differentiation, the DC/T-cell cluster microenvironment can also disrupt immune tolerance by interfering with Treg differentiation and function, thus participating in the pathogenesis of IBD. Both animal studies and human specimen analyses have shown a reduced frequency of FOXP3+ regulatory T cells within active lesions. Key cytokines secreted by DCs, including IL-6, TGF-β, IL-12, and IL-1β, have concentration-dependent regulatory effects on Tregs. IL-6 can inhibit the transcriptional activity and anti-inflammatory function of Tregs by inducing the expression of the kinase proviral integration site for Moloney murine leukemia virus 1 (PIM1), which phosphorylates FOXP3 at Ser422 (139). Although TGF-β is a key inducer of FOXP3 expression, it can synergize with IL-6 to promote FOXP3 protein degradation and inhibit Treg function in the inflammatory environment of IBD (140). Similarly, high concentrations of IL-1β significantly inhibit the differentiation of naive T cells into FOXP3+ iTregs as well as the expression of FOXP3 by upregulating hypoxia-inducible factor 1 alpha (HIF-1α) under TCR stimulation. In contrast, low IL-1β concentrations may have a Treg proliferation-inducing effect (141). IL-12 exhibits bidirectional regulation, elevating the expression of IL-2 receptors on effector T cells, while concomitantly downregulating that of IL-2R in Tregs, thereby competitively limiting the critical support of IL-2 for Treg survival and function (142). These mechanisms collectively lead to the inhibition of Treg function and exacerbate the immune imbalance in IBD (Figure 8). The relative contribution of these cytokine-mediated disruptions to Treg function may vary between CD and UC, reflecting their distinct inflammatory milieus. In addition, it should be noted that the TFH-DC axis is clearly distinct from the germinal-center–dependent paradigm of the classical TFH-B axis. To visualize this difference, the study provides a systematic side-by-side comparison of the core components of TFH-B versus TFH-DC interactions in Table 2, focusing on three dimensions —cytokine networks, co-stimulatory signals, and chemotactic axes —thereby highlighting the unique position of the TFH-DC axis in the progression of IBD (Table 2).
Figure 8. TFH cells mediate the recruitment of mature DCs and synergistically drive the formation of DC/T-cell clusters, thus promoting IBD pathology. TFH-derived membrane-bound LTα1β2 binds to LTβR on DCs, triggering a non-canonical NF-κB signaling cascade (via TRAF3 degradation/NIK stabilization) that induces chemokine (CXCL13, CCL19, CCL21) production. This recruits more immune cells, expanding the clusters. Within clusters, enhanced DC signals promote pro-inflammatory Th1/Th17 differentiation (e.g., via the IL-12-STAT4-T-bet-IFN-γ axis) while inhibiting Treg function through cytokines (IL-6, TGF-β, IL-12, IL-1β), collectively exacerbating intestinal.
Table 2. Systematic comparison of TFH-B versus TFH-DC interactions: analyzing the pathogenic significance and unique features of TFH-DC for IBD.
In summary, the pathogenesis of IBD can be reframed as a breakdown in subset-specific communication: pro-inflammatory DC subsets (e.g., cDC2, Mo-DC; Table 1) and TFH-lineage effectors (e.g., GC-TFH; Figure 4) engage in a vicious cycle, while regulatory counterparts (e.g., mregDC, TFR) fail to impose restraint, culminating in chronic intestinal inflammation.
5 Therapeutic targeting of the DC-TFH cell interactions delays IBD progression
Effective therapeutic strategies are built upon systematic summarizing and parsing of the DCs–TFH interaction mechanism. To this end, this study first systematically compares species-specific findings from animal models against the clinical characteristics of the corresponding diseases, and then uses the attached table to analyse their translational potential, thereby providing solid evidence-based support for the formulation of subsequent clinical intervention strategies (Table 3).
Table 3. Model-specific findings versus the clinical characteristics of IBD: analyzing translational relevance.
As previously mentioned, the interaction between DCs and TFH cells plays a central driving role in the occurrence and development of IBD through the establishment of a vicious cycle (DCs drive TFH cell differentiation, while TFH cells promote DC accumulation and DC/T-cell cluster formation). Therefore, disrupting this interaction has emerged as an important therapeutic strategy for IBD. Given the relative stability of DCs as innate immune cells, current therapeutic approaches mostly focus on inhibiting the development and function of TFH cells, thereby indirectly regulating DC-TFH cell interactions. It is noteworthy that the clinical application and evidence base for these therapies often differ between CD and UC. Aminosalicylates, including sulfasalazine and mesalazine, are conventional therapeutic agents primarily used in UC that mainly exert anti-inflammatory effects by inhibiting excessive immune cell activation. In vivo studies have shown that these drugs can downregulate the expression of the pro-inflammatory factor TNF-α and upregulate that of the anti-inflammatory factor IL-10, thereby inhibiting immune responses and promoting intestinal mucosal barrier repair (143–145). Crucially, given the important role of TNF-α in the promotion of TFH cell differentiation, aminosalicylates can indirectly influence the development of TFH cells by inhibiting this cytokine (143).
Prednisolone suppresses DC maturation through the GR –NF-κB axis, which in turn downregulates IL-6/IL-21 production, thereby impairing TFH cell differentiation and function. Ultimately, this leads to a reduction in germinal center reactions and autoantibody production. This pathway not only complements the traditional anti-inflammatory mechanism of glucocorticoids at the level of humoral immune suppression but also provides a theoretical basis for combination therapies targeting TFH cell in IBD (146). Furthermore, Cyclosporine A acts by blocking the calcineurin–NFAT axis, resulting in the downregulation of DC-derived IL-6/IL-21 and reduced expression of ICOS/PD-1 on TFH cell. This rapidly suppresses intestinal TFH cell differentiation and germinal center reactions during acute phases of IBD, thereby reducing autoantibody production (147, 148). Similarly, Tacrolimus inhibits the calcineurin–NFAT axis, leading to decreased DC-derived IL-6/IL-21 and reduced CD40L expression on CD4+ T cells. This similarly results in rapid suppression of intestinal TFH cell differentiation, germinal center reactions, and autoantibody generation during acute IBD flares (149, 150). Together, these agents provide a rational basis for the treatment of severe IBD refractory to corticosteroid therapy.
Randomized clinical trials and real-world clinical experience alike have demonstrated that ustekinumab —a monoclonal antibody targeting the p40 subunit shared by IL-12 and IL-23 (151), blocks the binding of both cytokines to their receptors and inhibits downstream pro-inflammatory signaling. As IL-23 plays a crucial role in maintaining the function of TFH cells, ustekinumab can also interfere with TFH cell development and homeostasis, thereby alleviating IBD inflammation (152). It is an approved therapy for both moderate-to-severe CD and UC. In the inflammatory microenvironment of IBD, tocilizumab, a monoclonal antibody targeting the IL-6 receptor, suppresses the generation of TFH cells by blocking IL-6 signaling and also maintains BCL-6 expression at low levels (153). While primarily used in other autoimmune diseases, its role in IBD remains investigational. Olamkicept, a soluble gp130-Fc fusion protein that selectively inhibits IL-6 trans-signaling, has shown efficacy and safety in clinical studies for active UC (154); however, excessive inhibition of IL-6 signaling, such as occurs with tocilizumab, can potentially exacerbate IBD (155). The abnormal elevation of TNF-α is a key feature of IBD. Anti-TNF-α monoclonal antibodies, such as infliximab and adalimumab, effectively reduce peripheral blood T-cell activation (manifested as the downregulation of CD25 expression); inhibit the secretion of pro-inflammatory factors such as IFN-γ, IL-13, IL-17A, and TNF; and suppress the proliferation of CD4+ and CD8+ T cells by neutralizing TNF-α (156, 157). These agents are cornerstone therapies for both CD and UC. Because TNF-α participates in the regulation of TFH cell differentiation, anti-TNF-α therapy can also indirectly affect the TFH cell pool.
Vedolizumab, an anti-integrin drug, prevents lymphocyte homing to the intestinal mucosa via the dual blockade of α4β7 and αEβ7 integrins, thereby inhibiting the initial activation of the intestinal mucosal immune system and limiting the local accumulation of effector T cells, including CD8+ T cells (158). The intestinal mucosa is a key site for TFH cell function. These cells express high levels of CXCR5 and migrate to the GC to assist B cells in differentiating into plasma cells and producing antibodies (159). By blocking lymphocyte homing, vedolizumab indirectly interferes with intestinal T-cell activation pathways, including TFH cell-mediated B cell assistance, thereby dampening local immune responses and alleviating IBD (160, 161). It is effective for inducing and maintaining remission in both UC and CD.
The JAK inhibitor upadacitinib—currently approved for moderate-to-severe UC and with emerging evidence in CD—simultaneously inhibits signal transduction mediated by key cytokines (such as IL-6, IL-12, and IL-23), influencing TFH cell development by blocking the JAK-STAT signaling pathway. This effectively reduces intestinal mucosal inflammation and helps control IBD progression (162).
S1P receptor modulators, such as Ozanimod (approved for moderate−to−severe UC and with Phase III evidence in CD) and Etrasimod (approved for UC and demonstrating efficacy in CD trials), reduce the homing of CD11c+ activated DCs to the intestinal mucosa while downregulating DC-derived IL-12/IL-23. This indirectly suppresses the TFH cell differentiation axis, leading to reduced infiltration of immune cells in the intestinal mucosa and promoting repair of the mucosal barrier, thereby alleviating clinical symptoms of IBD (163) (Table 4).
Table 4. Treatment strategy of the DC-TFH cell interactions delays IBD progression.
In addition, growing evidence suggests that traditional Chinese medicine and its active ingredients can also affect the progression of IBD through the regulation of TFH cell development and DC-TFH cell interactions. However, it should be noted that many preclinical studies utilize UC-like animal models [e.g., Dextran sulfate sodium (DSS)-induced colitis], and their findings may require further validation in CD-relevant models. For instance, the formula Sishen Wan alleviates colitis symptoms in mice by inhibiting the Bcl-6/Blimp-1 pathway and suppressing TFH cell differentiation (164). Paeoniflorin, the main active ingredient in Paeonia lactiflora, has been shown in a 3% DSS-induced UC mouse model to inhibit PI3K-AKT-dependent dendritic cell maturation, impair DC-derived IL-6-mediated TFH cell differentiation, and subsequently reduce IL-21 production and downstream inflammatory cascades, thereby ameliorating experimental colitis. This provides direct evidence supporting the “TCM monomer-DC-TFH interaction” paradigm for UC treatment (165).
Building on this successful paradigm, artesunate alleviates autoantibody responses in lupus-prone mice by blocking TFH differentiation via a JAK2-STAT3-Bcl-6-dependent mechanism (166); Xiehuo Xiaoying Decoction has been demonstrated to modulate the TFH/Tfr cell balance by suppressing TFH cell expansion and promoting Tfr cell proliferation, thereby delaying the progression of autoimmune-related diseases (167); ginsenoside can block recognition by TLRs and induce the expression of suppressor of cytokine signaling (SOCS), inhibit the PI3K-AKT and STAT signaling pathways, increase the Treg proportion, and inhibit TFH cell function (168–170); and luteolin has been shown to inhibit p-STAT1 and p-JAK1 expression related to TFH cell differentiation, block NF-κB signal transduction, and significantly reduce the levels of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), IL-8, and nitric oxide (NO) in colon tissue, thereby improving IBD-like symptoms (171). These studies collectively provide valuable insights for developing novel therapeutic strategies for IBD (Table 4).
6 Summary and prospects
IBD is characterized by a high incidence and complex pathogenesis. Recent research has revealed that the immunological interaction between DCs and TFH cells plays a key role in IBD occurrence and development. Nevertheless, significant gaps in current knowledge remain. First, direct spatial evidence of DC-TFH interactions in human IBD tissues is still limited. Second, the dynamics of their molecular interplay across different disease stages and subtypes are not fully elucidated. Finally, the potential long-term impact of targeting this axis on systemic immune surveillance warrants careful evaluation. While this axis appears central to both CD and UC, its specific cellular and molecular dynamics may be shaped by the distinct inflammatory milieus of each subtype. Building on emerging insights into how DC-TFH cell interactions drive IBD pathology, in this review, we summarized current clinical drug strategies aimed at targeting this axis to mitigate disease symptoms. However, the unavoidable side effects associated with these therapies limit their application prospects. Accordingly, further exploration of the unique advantages of TCM-notably, its multi-component, multi-target, and multi-pathway modulation of immune networks-holds considerable therapeutic promise for IBD. This approach may be particularly suited to address the heterogeneous immune dysregulation seen across IBD subtypes.
To address these knowledge gaps, future investigations should employ high-resolution technologies—such as single-cell RNA sequencing and spatial transcriptomics—to map the subset-specific interaction landscape between DCs and TFH cells in IBD tissues. Elucidating how distinct DC subsets (e.g., cDC1, cDC2, Mo DC, mregDC) communicate with TFH-lineage populations (including TFH, TFR, and cTFH) in a spatially organized manner will not only refine our understanding of disease mechanisms but also pave the way for subtype tailored therapeutic strategies in CD versus UC.
This high-resolution, subset-focused paradigm should also guide the investigation of traditional therapeutic agents, such as TCM. Although studies have shown that TCM can alleviate IBD symptoms by inhibiting the expression of key cytokines and transcription factors involved in TFH cell differentiation, thereby indirectly interfering with DC/TFH cell interactions. Nevertheless, direct experimental evidence confirming that TCM components act on the DC/TFH cell interface remains limited. Future research should prioritize integrating high-resolution technological platforms, such as single-cell RNA sequencing, multiplexed immunofluorescence in situ hybridization, and spatial transcriptomics, to systematically dissect the molecular mechanisms through which TCM regulates direct immune cell interactions, particularly between DCs and TFH cells. Crucially, these investigations should be conducted with explicit attention to distinguishing the profiles and interplay of these cells in CD versus UC, to uncover subtype-specific therapeutic targets. This will provide crucial directions for elucidating the immunopharmacological foundations of TCM in the treatment of IBD.
Author contributions
YL: Writing – original draft. YJ: Writing – original draft. ZZ: Writing – original draft. JL: Writing – review & editing. ZqZ: Visualization, Writing – original draft. LT: Visualization, Writing – original draft. XX: Visualization, Writing – original draft. SW: Conceptualization, Supervision, Writing – review & editing. MJ: Conceptualization, Funding acquisition, Supervision, Writing – review & editing. HL: Conceptualization, Funding acquisition, Supervision, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Scientific Research Fund of the Education Department of Yunnan Province (Grant No. 2025Y0582), which specifically funded the data collection; the Yunnan Provincial Department of Education Science Graduate Fund Project (Grant No. 2024Y377), which supported researcher salaries; and the Education Department of Yunnan Province (Grant No. 2023Y0464), which funded the experimental materials.
Conflict of interest
The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Glossary
IBD: inflammatory bowel disease
DCs: dendritic cells
TFH: T follicular helper
LTα1β2: lymphotoxin alpha 1 beta 2
CD: Crohn’s disease
UC: ulcerative colitis
CXCR5: C-X-C motif chemokine receptor 5, GCs, germinal centers
CXCL13: C-X-C motif chemokine 13
ICOSL: inducible co-stimulator ligand
IL-21: interleukin-21
Th1: T helper 1
cDCs: conventional dendritic cells
pDCs: plasmacytoid dendritic cells
PAMPs: pathogen-associated molecular patterns
PRRs: pattern recognition receptors
TLRs: Toll-like receptors
CLRs: C-type lectin receptors
SRs: scavenger receptors
TGF-β: transforming growth factor-beta
JAK1: Janus kinase 1
TYK2: tyrosine kinase 2
STAT1: signal transducer and activator of transcription 1
PI3K: phosphatidylinositol 3-kinase
PI3K: phosphatidylinositol 3-kinase
TGF-βRII: TGF-β
TGF-βRI: TGF-β
FKBP1A: FK506-binding protein 1A
SMAD: small mothers against decapentaplegic
R-SMADs: receptor-regulated small mothers against decapentaplegic (SMAD) proteins
Tregs: regulatory T cells
LPS: lipopolysaccharide
IRAK1/4: interleukin-1 receptor-associated kinase 1/4
MyD88: myeloid differentiation factor 88
TRAF6: tumor necrosis factor receptor-associated factor 6
TAK1: transforming growth factor β-activated kinase 1
NF-κB: nuclear factor-kappa B
MAPK: mitogen-activated protein kinase
Lck: lymphocyte-specific tyrosine kinase
ITAMs: immunoreceptor tyrosine-based activation motifs
ZAP-70: ζ-chain-associated protein kinase 70
PI3K: phosphatidylinositol 3-kinase
NFAT: nuclear factor of activated T-cells
AP-1: activator protein 1
CTLs: cytotoxic T lymphocytes
APCs: antigen-presenting cells
pre-TFH: precursor TFH
FDCs: follicular dendritic cells
SAP: SLAM-associated protein
SLAM: signaling lymphocytic activation molecule
IFN-γ: interferon-gamma
NETs: neutrophil extracellular traps
RIP1: receptor-interacting protein 1
IKK: inhibitor of nuclear factor kappa-B kinase
RelA: reticuloendotheliosis viral oncogene homolog A
CARMA1: CARD-containing MAGUK protein 1
BCL-10: B-cell lymphoma/leukemia 10
MALT1: mucosa-associated lymphoid tissue lymphoma translocation protein 1
PKCθ: protein kinase C theta
BTB: bric-à-brac
HDAC2: histone deacetylase 2
LTα: lymphotoxin-alpha
LTβR: lymphotoxin beta receptor
T-bet: T-box transcription factor
TNF-α: tumor necrosis factor-alpha
PIM1: proviral integration site for Moloney murine leukemia virus 1
HIF-1α: hypoxia-inducible factor 1 alpha
SOCS: suppressor of cytokine signaling
COX-2: cyclooxygenase-2
iNOS: inducible nitric oxide synthase
NO: nitric oxide
DSS: Dextran sulfate sodium.
References
1. Long Y, Xia C, Zeng X, Feng J, Ma Y, and Liu C. Altered phenotypes of colonic and peripheral blood follicular helper and follicular cytotoxic T cells in mice with DSS-induced colitis. J Inflammation Res. (2023) 16:2879–92. doi: 10.2147/JIR.S411373
2. Sairenji T, Collins KL, and Evans DV. An update on inflammatory bowel disease. Prim Care. (2017) 44:673–92. doi: 10.1016/j.pop.2017.07.010
3. Wan J, Shen J, Wu X, Zhong J, Chen Y, Zhu L, et al. Geographical heterogeneity in the disease characteristics and management of patients with inflammatory bowel disease, the preliminary results of a Chinese database for IBD (CHASE-IBD). Therap Adv Gastroenterol. (2023) 16:1108393343. doi: 10.1177/17562848231210367
4. Rogler G, Singh A, Kavanaugh A, and Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. (2021) 161:1118–32. doi: 10.1053/j.gastro.2021.07.042
5. Eaden JA, Abrams KR, and Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. (2001) 48:526–35. doi: 10.1136/gut.48.4.526
6. Mak WY, Zhao M, Ng SC, and Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol. (2020) 35:380–89. doi: 10.1111/jgh.14872
7. Jarmakiewicz-Czaja S, Zielinska M, Sokal A, and Filip R. Genetic and epigenetic etiology of inflammatory bowel disease: an update. Genes (Basel). (2022) 13:2388. doi: 10.3390/genes13122388
8. Lee JWJ, Plichta D, Hogstrom L, Borren NZ, Lau H, Gregory SM, et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell Host Microbe. (2021) 29:1294–304. doi: 10.1016/j.chom.2021.06.019
9. Haneishi Y, Furuya Y, Hasegawa M, Picarelli A, Rossi M, and Miyamoto J. Inflammatory bowel diseases and gut microbiota. Int J Mol Sci. (2023) 24:3817. doi: 10.3390/ijms24043817
10. Lee M and Chang EB. Inflammatory bowel diseases (IBD) and the microbiome-searching the crime scene for clues. Gastroenterology. (2021) 160:524–37. doi: 10.1053/j.gastro.2020.09.056
11. Kiilerich KF, Andresen T, Darbani B, Gregersen LHK, Liljensoe A, Bennike TB, et al. Advancing inflammatory bowel disease treatment by targeting the innate immune system and precision drug delivery. Int J Mol Sci. (2025) 26:575. doi: 10.3390/ijms26020575
12. Geremia A, Biancheri P, Allan P, Corazza GR, and Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. (2014) 13:3–10. doi: 10.1016/j.autrev.2013.06.004
13. Wallace KL, Zheng L, Kanazawa Y, and Shih DQ. Immunopathology of inflammatory bowel disease. World J Gastroenterol. (2014) 20:6–21. doi: 10.3748/wjg.v20.i1.6
14. Hu C, Liao S, Lv L, Li C, and Mei Z. Intestinal immune imbalance is an alarm in the development of IBD. Mediators Inflammation. (2023) 2023:1073984. doi: 10.1155/2023/1073984
15. Bai X, Chen S, Chi X, Xie B, Guo X, Feng H, et al. Reciprocal regulation of T follicular helper cells and dendritic cells drives colitis development. Nat Immunol. (2024) 25:1383–94. doi: 10.1038/s41590-024-01882-1
16. Chen Z, Zheng Q, Wang Y, An X, Yirga SK, Lin D, et al. CXCL13/CXCR5 axis facilitates TFH expansion and correlates with disease severity in adults with immune thrombocytopenia. Thromb Res. (2024) 244:109196. doi: 10.1016/j.thromres.2024.109196
17. Bouteau A, Kervevan J, Su Q, Zurawski SM, Contreras V, Dereuddre-Bosquet N, et al. DC subsets regulate humoral immune responses by supporting the differentiation of distinct tfh cells. Front Immunol. (2019) 10:1134. doi: 10.3389/fimmu.2019.01134
18. Krishnaswamy JK, Alsen S, Yrlid U, Eisenbarth SC, and Williams A. Determination of T follicular helper cell fate by dendritic cells. Front Immunol. (2018) 9:2169. doi: 10.3389/fimmu.2018.02169
19. Qi J, Liu C, Bai Z, Li X, and Yao G. T follicular helper cells and T follicular regulatory cells in autoimmune diseases. Front Immunol. (2023) 14:1178792. doi: 10.3389/fimmu.2023.1178792
20. Long D, Chen Y, Wu H, Zhao M, and Lu Q. Clinical significance and immunobiology of IL-21 in autoimmunity. J Autoimmun. (2019) 99:1–14. doi: 10.1016/j.jaut.2019.01.013
21. Ren HM, Lukacher AE, Rahman ZSM, and Olsen NJ. New developments implicating IL-21 in autoimmune disease. J Autoimmun. (2021) 122:102689. doi: 10.1016/j.jaut.2021.102689
22. Steinman R. Ralph Steinman--pioneering new perspectives on the immune system and infectious diseases. Interviewed by Marilynn Larkin. Lancet Infect Dis. (2003) 3:383–86. doi: 10.1016/s1473-3099(03)00661-3
23. Rowley DA and Fitch FW. The road to the discovery of dendritic cells, a tribute to Ralph Steinman. Cell Immunol. (2012) 273:95–8. doi: 10.1016/j.cellimm.2012.01.002
24. Tang L, Zhang R, Zhang X, and Yang L. Personalized neoantigen-pulsed DC vaccines: advances in clinical applications. Front Oncol. (2021) 11:701777. doi: 10.3389/fonc.2021.701777
26. Wehr P, Purvis H, Law S, and Thomas R. Dendritic cells, T cells and their interaction in rheumatoid arthritis. Clin Exp Immunol. (2019) 196:12–27. doi: 10.1111/cei.13256
27. Oth T, Vanderlocht J, Van Elssen CHMJ, Bos GMJ, and Germeraad WTV. Pathogen-associated molecular patterns induced crosstalk between dendritic cells, T helper cells, and natural killer helper cells can improve dendritic cell vaccination. Mediators Inflammation. (2016) 2016:5740373. doi: 10.1155/2016/5740373
28. Dudek AM, Martin S, Garg AD, and Agostinis P. Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity. Front Immunol. (2013) 4:438. doi: 10.3389/fimmu.2013.00438
29. Sallusto F, Cella M, Danieli C, and Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med. (1995) 182:389–400. doi: 10.1084/jem.182.2.389
30. Schreibelt G, Klinkenberg LJJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, et al. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood. (2012) 119:2284–92. doi: 10.1182/blood-2011-08-373944
31. Zhu X, Ramos TV, Gras-Masse H, Kaplan BE, and BenMohamed L. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol. (2004) 34:3102–14. doi: 10.1002/eji.200425166
32. Verbovetski I, Bychkov H, Trahtemberg U, Shapira I, Hareuveni M, Ben-Tal O, et al. Opsonization of apoptotic cells by autologous iC3b facilitates clearance by immature dendritic cells, down-regulates DR and CD86, and up-regulates CC chemokine receptor 7. J Exp Med. (2002) 196:1553–61. doi: 10.1084/jem.20020263
33. Kariko K and Weissman D. Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development. Curr Opin Drug Discov Devel. (2007) 10:523–32.
34. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. (2004) 303:1526–29. doi: 10.1126/science.1093620
35. Sedaghat B, Stephenson R, and Toth I. Targeting the mannose receptor with mannosylated subunit vaccines. Curr Med Chem. (2014) 21:3405–18. doi: 10.2174/0929867321666140826115552
36. de Rijke YB, Jurgens G, Hessels EM, Hermann A, and van Berkel TJ. In vivo fate and scavenger receptor recognition of oxidized lipoprotein[a] isoforms in rats. J Lipid Res. (1992) 33:1315–25. doi: 10.1016/S0022-2275(20)40545-0
37. Bosteels V, Marechal S, De Nolf C, Rennen S, Maelfait J, Tavernier SJ, et al. LXR signaling controls homeostatic dendritic cell maturation. Sci Immunol. (2023) 8:eadd3955. doi: 10.1126/sciimmunol.add3955
38. Mahnke K, Johnson TS, Ring S, and Enk AH. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J Dermatol Sci. (2007) 46:159–67. doi: 10.1016/j.jdermsci.2007.03.002
39. Kim MK and Kim J. Properties of immature and mature dendritic cells: phenotype, morphology, phagocytosis, and migration. RSC Adv. (2019) 9:11230–38. doi: 10.1039/c9ra00818g
40. Reis M, Mavin E, Nicholson L, Green K, Dickinson AM, and Wang X. Mesenchymal stromal cell-derived extracellular vesicles attenuate dendritic cell maturation and function. Front Immunol. (2018) 9:2538. doi: 10.3389/fimmu.2018.02538
41. Chen L, Qiu M, He W, Huang A, and Liu J. Functional study of immature dendritic cells co-transfected with IL-10 and TGF-beta 1 genes in vitro. Mol Biol Rep. (2012) 39:6633–39. doi: 10.1007/s11033-012-1468-4
42. Shaw MH, Freeman GJ, Scott MF, Fox BA, Bzik DJ, Belkaid Y, et al. Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-gamma-dependent IL-10 reactivation. J Immunol. (2006) 176:7263–71. doi: 10.4049/jimmunol.176.12.7263
43. Li D, Liu L, Du X, Ma W, Zhang J, and Piao W. MiRNA-374b-5p and miRNA-106a-5p are related to inflammatory bowel disease via regulating IL-10 and STAT3 signaling pathways. BMC Gastroenterol. (2022) 22:492. doi: 10.1186/s12876-022-02533-1
44. Liu Q, Zhong D, Zhang X, and Li G. IL-10 targets Th1/Th2 balance in vascular dementia. Eur Rev Med Pharmacol Sci. (2018) 22:5614–19. doi: 10.26355/eurrev_201809_15826
45. Cole TS, Zhang M, Standiford TJ, Newstead M, Luther J, Zhang J, et al. IRAK-M modulates expression of IL-10 and cell surface markers CD80 and MHC II after bacterial re-stimulation of tolerized dendritic cells. Immunol Lett. (2012) 144:49–59. doi: 10.1016/j.imlet.2012.03.006
46. Ruffner MA, Kim SH, Bianco NR, Francisco LM, Sharpe AH, and Robbins PD. B7-1/2, but not PD-L1/2 molecules, are required on IL-10-treated tolerogenic DC and DC-derived exosomes for in vivo function. Eur J Immunol. (2009) 39:3084–90. doi: 10.1002/eji.200939407
47. Taylor A, Verhagen J, Blaser K, Akdis M, and Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology. (2006) 117:433–42. doi: 10.1111/j.1365-2567.2006.02321.x
48. Shi Y and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. (2003) 113:685–700. doi: 10.1016/s0092-8674(03)00432-x
49. Miyazawa K and Miyazono K. Regulation of TGF-beta family signaling by inhibitory smads. Cold Spring Harb Perspect Biol. (2017) 9:a022095. doi: 10.1101/cshperspect.a022095
50. Acuto O, Di Bartolo V, and Michel F. Tailoring T-cell receptor signals by proximal negative feedback mechanisms. Nat Rev Immunol. (2008) 8:699–712. doi: 10.1038/nri2397
51. Takeuchi O and Akira S. Pattern recognition receptors and inflammation. Cell. (2010) 140:805–20. doi: 10.1016/j.cell.2010.01.022
52. Miao Y, Jiang M, Qi L, Yang D, Xiao W, and Fang F. BCAP regulates dendritic cell maturation through the dual-regulation of NF-kappaB and PI3K/AKT signaling during infection. Front Immunol. (2020) 11:250. doi: 10.3389/fimmu.2020.00250
53. Aki D, Minoda Y, Yoshida H, Watanabe S, Yoshida R, Takaesu G, et al. Peptidoglycan and lipopolysaccharide activate PLCgamma2, leading to enhanced cytokine production in macrophages and dendritic cells. Genes Cells. (2008) 13:199–208. doi: 10.1111/j.1365-2443.2007.01159.x
54. Forloni M, Albini S, Limongi MZ, Cifaldi L, Boldrini R, Nicotra MR, et al. NF-kappaB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells. Cancer Res. (2010) 70:916–24. doi: 10.1158/0008-5472.CAN-09-2582
55. Qin T, Ren Z, Huang Y, Song Y, Lin D, Li J, et al. Selenizing Hericium erinaceus polysaccharides induces dendritic cells maturation through MAPK and NF-kappaB signaling pathways. Int J Biol Macromol. (2017) 97:287–98. doi: 10.1016/j.ijbiomac.2017.01.039
56. Kim HW, Cho SI, Bae S, Kim H, Kim Y, Hwang Y, et al. Vitamin C up-regulates expression of CD80, CD86 and MHC class II on dendritic cell line, DC-1 via the activation of p38 MAPK. Immune Netw. (2012) 12:277–83. doi: 10.4110/in.2012.12.6.277
57. Yang F, Li X, Yang Y, Ayivi-Tosuh SM, Wang F, Li H, et al. A polysaccharide isolated from the fruits of Physalis alkekengi L. induces RAW264.7 macrophages activation via TLR2 and TLR4-mediated MAPK and NF-kappaB signaling pathways. Int J Biol Macromol. (2019) 140:895–906. doi: 10.1016/j.ijbiomac.2019.08.174
58. Blander JM. Different routes of MHC-I delivery to phagosomes and their consequences to CD8 T cell immunity. Semin Immunol. (2023) 66:101713. doi: 10.1016/j.smim.2023.101713
59. Park MJ, Ryu HS, Kim JS, Lee HK, Kang JS, Yun J, et al. Platycodon grandiflorum polysaccharide induces dendritic cell maturation via TLR4 signaling. Food Chem Toxicol. (2014) 72:212–20. doi: 10.1016/j.fct.2014.07.011
60. Ishina IA, Zakharova MY, Kurbatskaia IN, Mamedov AE, Belogurov AAJ, and Gabibov AG. MHC class II presentation in autoimmunity. Cells. (2023) 12:314. doi: 10.3390/cells12020314
62. Kuhns MS, Davis MM, and Garcia KC. Deconstructing the form and function of the TCR/CD3 complex. Immunity. (2006) 24:133–39. doi: 10.1016/j.immuni.2006.01.006
63. Giardino Torchia ML, Dutta D, Mittelstadt PR, Guha J, Gaida MM, Fish K, et al. Intensity and duration of TCR signaling is limited by p38 phosphorylation of ZAP-70(T293) and destabilization of the signalosome. Proc Natl Acad Sci U.S.A. (2018) 115:2174–79. doi: 10.1073/pnas.1713301115
64. Hosoe Y, Miyanoiri Y, Re S, Ochi S, Asahina Y, Kawakami T, et al. Structural dynamics of the N-terminal SH2 domain of PI3K in its free and CD28-bound states. FEBS J. (2023) 290:2366–78. doi: 10.1111/febs.16666
65. Lin J, Chen L, and Kane LP. Murine Tim-1 is excluded from the immunological synapse. F1000Res. (2012) 1:10. doi: 10.12688/f1000research.1-10.v2
66. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, and Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U.S.A. (1998) 95:258–63. doi: 10.1073/pnas.95.1.258
67. Deenick EK and Ma CS. The regulation and role of T follicular helper cells in immunity. Immunology. (2011) 134:361–67. doi: 10.1111/j.1365-2567.2011.03487.x
68. Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, Hill KM, et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature. (2005) 435:452–58. doi: 10.1038/nature03555
69. Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, Barnett B, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science. (2009) 325:1006–10. doi: 10.1126/science.1175870
70. Yu D, Rao S, Tsai LM, Lee SK, He Y, Sutcliffe EL, et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity. (2009) 31:457–68. doi: 10.1016/j.immuni.2009.07.002
71. Xu W, Zhao X, Wang X, Feng H, Gou M, Jin W, et al. The transcription factor tox2 drives T follicular helper cell development via regulating chromatin accessibility. Immunity. (2019) 51:826–39. doi: 10.1016/j.immuni.2019.10.006
72. Matsuda-Lennikov M, Ohigashi I, and Takahama Y. Tissue-specific proteasomes in generation of MHC class I peptides and CD8(+) T cells. Curr Opin Immunol. (2022) 77:102217. doi: 10.1016/j.coi.2022.102217
73. Kajino K, Kajino Y, and Greene MI. Fas- and perforin-independent mechanism of cytotoxic T lymphocyte. Immunol Res. (1998) 17:89–93. doi: 10.1007/BF02786434
74. Erskine CL, Krco CJ, Hedin KE, Borson ND, Kalli KR, Behrens MD, et al. MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells. J Immunol. (2011) 187:316–24. doi: 10.4049/jimmunol.1100658
75. Pattarini L, Trichot C, Bogiatzi S, Grandclaudon M, Meller S, Keuylian Z, et al. TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand. J Exp Med. (2017) 214:1529–46. doi: 10.1084/jem.20150402
76. Betzler AC, Ushmorov A, and Brunner C. The transcriptional program during germinal center reaction - a close view at GC B cells, Tfh cells and Tfr cells. Front Immunol. (2023) 14:1125503. doi: 10.3389/fimmu.2023.1125503
77. Jogdand GM, Mohanty S, and Devadas S. Regulators of tfh cell differentiation. Front Immunol. (2016) 7:520. doi: 10.3389/fimmu.2016.00520
78. Kumar S, Basto AP, Ribeiro F, Almeida SCP, Campos P, Peres C, et al. Specialized Tfh cell subsets driving type-1 and type-2 humoral responses in lymphoid tissue. Cell Discov. (2024) 10:64. doi: 10.1038/s41421-024-00681-0
79. He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, et al. Circulating precursor CCR7(lo)PD-1(hi) CXCR5+ CD4+ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity. (2013) 39:770–81. doi: 10.1016/j.immuni.2013.09.007
80. Bentebibel S, Schmitt N, Banchereau J, and Ueno H. Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4+ T-cell subset specialized for B-cell help outside germinal centers. Proc Natl Acad Sci U.S.A. (2011) 108:E488–97. doi: 10.1073/pnas.1100898108
81. Rao VK, Webster S, Dalm VASH, Šedivá A, van Hagen PM, Holland S, et al. Effective “activated PI3Kδ syndrome”-targeted therapy with the PI3Kδ inhibitor leniolisib. Blood. (2017) 130:2307–16. doi: 10.1182/blood-2017-08-801191
82. Linterman MA, Pierson W, Lee SK, Kallies A, Kawamoto S, Rayner TF, et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nat Med. (2011) 17:975–82. doi: 10.1038/nm.2425
83. Long Y, Xia C, Xu L, Liu C, Fan C, Bao H, et al. The imbalance of circulating follicular helper T cells and follicular regulatory T cells is associated with disease activity in patients with ulcerative colitis. Front Immunol. (2020) 11:104. doi: 10.3389/fimmu.2020.00104
84. Wei X and Niu X. T follicular helper cells in autoimmune diseases. J Autoimmun. (2023) 134:102976. doi: 10.1016/j.jaut.2022.102976
85. Wang Z, Li M, Zhou M, Zhang Y, Yang J, Cao Y, et al. A novel rabies vaccine expressing CXCL13 enhances humoral immunity by recruiting both T follicular helper and germinal center B cells. J Virol. (2017) 91:10. doi: 10.1128/JVI.01956-16
86. Bekele Feyissa Y, Chiodi F, Sui Y, and Berzofsky JA. The role of CXCL13 in antibody responses to HIV-1 infection and vaccination. Front Immunol. (2021) 12:638872. doi: 10.3389/fimmu.2021.638872
87. Ji L, Sun X, Zhang X, Zhou Z, Yu Z, Zhu X, et al. Mechanism of follicular helper T cell differentiation regulated by transcription factors. J Immunol Res. (2020) 2020:1826587. doi: 10.1155/2020/1826587
88. Ma CS, Nichols KE, and Tangye SG. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu Rev Immunol. (2007) 25:337–79. doi: 10.1146/annurev.immunol.25.022106.141651
89. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, and Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med. (2000) 192:1553–62. doi: 10.1084/jem.192.11.1553
90. Webb LMC and Linterman MA. Signals that drive T follicular helper cell formation. Immunology. (2017) 152:185–94. doi: 10.1111/imm.12778
91. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. (2011) 29:621–63. doi: 10.1146/annurev-immunol-031210-101400
92. Lu J, Zhou H, Chen Y, Xia X, Yang J, Ma J, et al. Tfh cell-derived small extracellular vesicles exacerbate the severity of collagen-induced arthritis by enhancing B-cell responses. J Autoimmun. (2024) 146:103235. doi: 10.1016/j.jaut.2024.103235
93. Wang Y, Han J, Yang G, Zheng S, Zhou G, Liu X, et al. Therapeutic potential of the secreted Kazal-type serine protease inhibitor SPINK4 in colitis. Nat Commun. (2024) 15:5874. doi: 10.1038/s41467-024-50048-y
94. Burke KP, Chaudhri A, Freeman GJ, and Sharpe AH. The B7:CD28 family and friends: Unraveling coinhibitory interactions. Immunity. (2024) 57:223–44. doi: 10.1016/j.immuni.2024.01.013
95. Courtney AH, Shvets AA, Lu W, Griffante G, Mollenauer M, Horkova V, et al. CD45 functions as a signaling gatekeeper in T cells. Sci Signal. (2019) 12:eaaw8151. doi: 10.1126/scisignal.aaw8151
96. Cronin SJF and Penninger JM. From T-cell activation signals to signaling control of anti-cancer immunity. Immunol Rev. (2007) 220:151–68. doi: 10.1111/j.1600-065X.2007.00570.x
97. Burbach BJ, Medeiros RB, Mueller KL, and Shimizu Y. T-cell receptor signaling to integrins. Immunol Rev. (2007) 218:65–81. doi: 10.1111/j.1600-065X.2007.00527.x
98. So T, Soroosh P, Eun S, Altman A, and Croft M. Antigen-independent signalosome of CARMA1, PKCtheta, and TNF receptor-associated factor 2 (TRAF2) determines NF-kappaB signaling in T cells. Proc Natl Acad Sci U.S.A. (2011) 108:2903–08. doi: 10.1073/pnas.1008765108
99. Fracchia KM, Pai CY, and Walsh CM. Modulation of T cell metabolism and function through calcium signaling. Front Immunol. (2013) 4:324. doi: 10.3389/fimmu.2013.00324
100. Fu N, Xie F, Sun Z, and Wang Q. The OX40/OX40L axis regulates T follicular helper cell differentiation: implications for autoimmune diseases. Front Immunol. (2021) 12:670637. doi: 10.3389/fimmu.2021.670637
101. Kawamata S, Hori T, Imura A, Takaori-Kondo A, and Uchiyama T. Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation. J Biol Chem. (1998) 273:5808–14. doi: 10.1074/jbc.273.10.5808
102. Hauer J, Puschner S, Ramakrishnan P, Simon U, Bongers M, Federle C, et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci U.S.A. (2005) 102:2874–79. doi: 10.1073/pnas.0500187102
103. Tahiliani V, Hutchinson TE, Abboud G, Croft M, and Salek-Ardakani S. OX40 cooperates with ICOS to amplify follicular th cell development and germinal center reactions during infection. J Immunol. (2017) 198:218–28. doi: 10.4049/jimmunol.1601356
104. So T and Croft M. Regulation of PI-3-kinase and akt signaling in T lymphocytes and other cells by TNFR family molecules. Front Immunol. (2013) 4:139. doi: 10.3389/fimmu.2013.00139
105. Karpf L, Trichot C, Faucheux L, Legbre I, Grandclaudon M, Lahoute C, et al. A multivariate modeling framework to quantify immune checkpoint context-dependent stimulation on T cells. Cell Discov. (2022) 8:1. doi: 10.1038/s41421-021-00352-4
106. Marinelarena A, Bhattacharya P, Kumar P, Maker AV, and Prabhakar BS. Identification of a novel OX40L(+) dendritic cell subset that selectively expands regulatory T cells. Sci Rep. (2018) 8:14940. doi: 10.1038/s41598-018-33307-z
107. Crotty S, Johnston RJ, and Schoenberger SP. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol. (2010) 11:114–20. doi: 10.1038/ni.1837
108. Ma CS, Deenick EK, Batten M, and Tangye SG. The origins, function, and regulation of T follicular helper cells. J Exp Med. (2012) 209:1241–53. doi: 10.1084/jem.20120994
109. Vasanwala FH, Kusam S, Toney LM, and Dent AL. Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol. (2002) 169:1922–29. doi: 10.4049/jimmunol.169.4.1922
110. Sheikh AA and Groom JR. Transcription tipping points for T follicular helper cell and T-helper 1 cell fate commitment. Cell Mol Immunol. (2021) 18:528–38. doi: 10.1038/s41423-020-00554-y
111. Kroenke MA, Eto D, Locci M, Cho M, Davidson T, Haddad EK, et al. Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation. J Immunol. (2012) 188:3734–44. doi: 10.4049/jimmunol.1103246
112. Schmitt N, Morita R, Bourdery L, Bentebibel SE, Zurawski SM, Banchereau J, et al. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity. (2009) 31:158–69. doi: 10.1016/j.immuni.2009.04.016
113. Verheye E, Bravo Melgar J, Deschoemaeker S, Raes G, Maes A, De Bruyne E, et al. Dendritic cell-based immunotherapy in multiple myeloma: challenges, opportunities, and future directions. Int J Mol Sci. (2022) 23:904. doi: 10.3390/ijms23020904
114. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, and O’Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. (2004) 202:139–56. doi: 10.1111/j.0105-2896.2004.00211.x
115. Weinstein JS, Laidlaw BJ, Lu Y, Wang JK, Schulz VP, Li N, et al. STAT4 and T-bet control follicular helper T cell development in viral infections. J Exp Med. (2018) 215:337–55. doi: 10.1084/jem.20170457
116. Yin X, Chen S, and Eisenbarth SC. Dendritic cell regulation of T helper cells. Annu Rev Immunol. (2021) 39:759–90. doi: 10.1146/annurev-immunol-101819-025146
117. Powell MD, Read KA, Sreekumar BK, Jones DM, and Oestreich KJ. IL-12 signaling drives the differentiation and function of a TH1-derived TFH1-like cell population. Sci Rep. (2019) 9:13991. doi: 10.1038/s41598-019-50614-1
118. Chang Y, Bach L, Hasiuk M, Wen L, Elmzzahi T, Tsui C, et al. TGF-beta specifies T(FH) versus T(H)17 cell fates in murine CD4(+) T cells through c-Maf. Sci Immunol. (2024) 9:eadd4818. doi: 10.1126/sciimmunol.add4818
119. Vinuesa CG, Linterman MA, Yu D, and MacLennan ICM. Follicular helper T cells. Annu Rev Immunol. (2016) 34:335–68. doi: 10.1146/annurev-immunol-041015-055605
120. Bao K, Isik Can U, Miller MM, Brown IK, Dell’Aringa M, Dooms H, et al. A bifurcated role for c-Maf in Th2 and Tfh2 cells during helminth infection. Mucosal Immunol. (2023) 16:357–72. doi: 10.1016/j.mucimm.2023.04.002
121. Nie H, Lin P, Zhang Y, Wan Y, Li J, Yin C, et al. Single-cell meta-analysis of inflammatory bowel disease with scIBD. Nat Comput Sci. (2023) 3:522–31. doi: 10.1038/s43588-023-00464-9
122. Lv H, Mu Y, Zhang C, Zhao M, Jiang P, Xiao S, et al. Comparative analysis of single-cell transcriptome reveals heterogeneity and commonality in the immune microenvironment of colorectal cancer and inflammatory bowel disease. Front Immunol. (2024) 15:1356075. doi: 10.3389/fimmu.2024.1356075
123. Chen X, Ma W, Zhang T, Wu L, and Qi H. Phenotypic Tfh development promoted by CXCR5-controlled re-localization and IL-6 from radiation-resistant cells. Protein Cell. (2015) 6:825–32. doi: 10.1007/s13238-015-0210-0
124. Gensous N, Charrier M, Duluc D, Contin-Bordes C, Truchetet M, Lazaro E, et al. T follicular helper cells in autoimmune disorders. Front Immunol. (2018) 9:1637. doi: 10.3389/fimmu.2018.01637
125. Zhang R, Qi C, Hu Y, Shan Y, Hsieh Y, Xu F, et al. T follicular helper cells restricted by IRF8 contribute to T cell-mediated inflammation. J Autoimmun. (2019) 96:113–22. doi: 10.1016/j.jaut.2018.09.001
126. Harpur CM, Kato Y, Dewi ST, Stankovic S, Johnson DN, Bedoui S, et al. Classical type 1 dendritic cells dominate priming of th1 responses to herpes simplex virus type 1 skin infection. J Immunol (Baltimore Md.: 1950). (2019) 202:653–63. doi: 10.4049/jimmunol.1800218
127. This S and Paidassi H. New perspectives on the regulation of germinal center reaction via αvβ8- mediated activation of TGFβ. Front Immunol. (2022) 13:942468. doi: 10.3389/fimmu.2022.942468
128. Hilligan KL and Ronchese F. Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses. Cell Mol Immunol. (2020) 17:587–99. doi: 10.1038/s41423-020-0465-0
129. Sivakumar S, Jainarayanan A, Arbe-Barnes E, Sharma PK, Leathlobhair MN, Amin S, et al. Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms. Nat Commun. (2025) 16:1397. doi: 10.1038/s41467-024-55424-2
130. Fernandes MT, Ghezzo MN, Silveira AB, Kalathur RK, Povoa V, Ribeiro AR, et al. Lymphotoxin-beta receptor in microenvironmental cells promotes the development of T-cell acute lymphoblastic leukaemia with cortical/mature immunophenotype. Br J Haematol. (2015) 171:736–51. doi: 10.1111/bjh.13760
131. Yang X and Sun S. Targeting signaling factors for degradation, an emerging mechanism for TRAF functions. Immunol Rev. (2015) 266:56–71. doi: 10.1111/imr.12311
132. Yang M, Sun L, Han J, Zheng C, Liang H, Zhu J, et al. Biological characteristics of transcription factor RelB in different immune cell types: implications for the treatment of multiple sclerosis. Mol Brain. (2019) 12:115. doi: 10.1186/s13041-019-0532-6
133. Kazanietz MG, Durando M, and Cooke M. CXCL13 and its receptor CXCR5 in cancer: inflammation, immune response, and beyond. Front Endocrinol (Lausanne). (2019) 10:471. doi: 10.3389/fendo.2019.00471
134. Kikuchi K, Yanagawa Y, and Onoe K. CCR7 ligand-enhanced phagocytosis of various antigens in mature dendritic cells-time course and antigen distribution different from phagocytosis in immature dendritic cells. Microbiol Immunol. (2005) 49:535–44. doi: 10.1111/j.1348-0421.2005.tb03759.x
135. Zhang Y, Zhang Y, Gu W, and Sun B. TH1/TH2 cell differentiation and molecular signals. Adv Exp Med Biol. (2014) 841:15–44. doi: 10.1007/978-94-017-9487-9_2
136. Lei D, Liu L, Xie S, Ji H, Guo Y, Ma T, et al. Dexmedetomidine Directs T Helper Cells toward Th1 Cell Differentiation via the STAT1-T-Bet Pathway. BioMed Res Int. (2021) 2021:3725316. doi: 10.1155/2021/3725316
137. Soderquest K, Hertweck A, Giambartolomei C, Henderson S, Mohamed R, Goldberg R, et al. Genetic variants alter T-bet binding and gene expression in mucosal inflammatory disease. PLoS Genet. (2017) 13:e1006587. doi: 10.1371/journal.pgen.1006587
138. Woznicki JA, Saini N, Flood P, Rajaram S, Lee CM, Stamou P, et al. TNF-alpha synergises with IFN-gamma to induce caspase-8-JAK1/2-STAT1-dependent death of intestinal epithelial cells. Cell Death Dis. (2021) 12:864. doi: 10.1038/s41419-021-04151-3
139. Li Z, Lin F, Zhuo C, Deng G, Chen Z, Yin S, et al. PIM1 kinase phosphorylates the human transcription factor FOXP3 at serine 422 to negatively regulate its activity under inflammation. J Biol Chem. (2014) 289:26872–81. doi: 10.1074/jbc.M114.586651
140. Gao Z, Gao Y, Li Z, Chen Z, Lu D, Tsun A, et al. Synergy between IL-6 and TGF-beta signaling promotes FOXP3 degradation. Int J Clin Exp Pathol. (2012) 5:626–33.
141. Feldhoff LM, Rueda CM, Moreno-Fernandez ME, Sauer J, Jackson CM, Chougnet CA, et al. IL-1beta induced HIF-1alpha inhibits the differentiation of human FOXP3(+) T cells. Sci Rep. (2017) 7:465. doi: 10.1038/s41598-017-00508-x
142. Zhao J, Zhao J, and Perlman S. Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-gamma, IL-2 and IL-2R. PLoS One. (2012) 7:e46241. doi: 10.1371/journal.pone.0046241
143. Chen L, Li X, and Gu Q. Chimonanthus salicifolius extract alleviates DSS-induced colitis and regulates gut microbiota in mice. Food Sci Nutr. (2023) 11:3019–30. doi: 10.1002/fsn3.3282
144. El-Baz AM, Khodir AE, Adel El-Sokkary MM, and Shata A. The protective effect of Lactobacillus versus 5-aminosalicylic acid in ulcerative colitis model by modulation of gut microbiota and Nrf2/Ho-1 pathway. Life Sci. (2020) 256:117927. doi: 10.1016/j.lfs.2020.117927
145. Wang J, Wang X, Jiang M, Lang T, Wan L, and Dai J. 5-aminosalicylic acid alleviates colitis and protects intestinal barrier function by modulating gut microbiota in mice. Naunyn Schmiedebergs Arch Pharmacol. (2025) 398:3681–95. doi: 10.1007/s00210-024-03485-x
146. Ma L, Zhang L, Zhuang Y, Ding Y, and Chen J. Lactobacillus improves the effects of prednisone on autoimmune hepatitis via gut microbiota-mediated follicular helper T cells. Cell Commun Signal. (2022) 20:83. doi: 10.1186/s12964-021-00819-7
147. Yang Q, Zhang F, Chen H, Hu Y, Yang N, Yang W, et al. The differentiation courses of the Tfh cells: a new perspective on autoimmune disease pathogenesis and treatment. Biosci Rep. (2024) 44:BSR20231723. doi: 10.1042/BSR20231723
148. Steines L, Poth H, Schuster A, Amann K, Banas B, and Bergler T. Disruption of tfh:B cell interactions prevents antibody-mediated rejection in a kidney transplant model in rats: impact of calcineurin inhibitor dose. Front Immunol. (2021) 12:657894. doi: 10.3389/fimmu.2021.657894
149. Lv W, Zhang D, He T, Liu Y, Shao L, Lv Z, et al. Combination of Lactobacillus plantarum improves the effects of tacrolimus on colitis in a mouse model. Front Cell Infect Microbiol. (2023) 13:1130820. doi: 10.3389/fcimb.2023.1130820
150. Kraaijeveld R, Li Y, Yan L, de Leur K, Dieterich M, Peeters AMA, et al. Inhibition of T helper cell differentiation by tacrolimus or sirolimus results in reduced B-cell activation: effects on T follicular helper cells. Transplant Proc. (2019) 51:3463–73. doi: 10.1016/j.transproceed.2019.08.039
151. D’Amico F, Peyrin-Biroulet L, and Danese S. Ustekinumab in crohn’s disease: new data for positioning in treatment algorithm. J Crohns Colitis. (2022) 16:ii30–41. doi: 10.1093/ecco-jcc/jjac011
152. Globig A, Sommer NP, Wild K, Schardey J, Zoldan K, Thomann AK, et al. Ustekinumab inhibits T follicular helper cell differentiation in patients with crohn’s disease. Cell Mol Gastroenterol Hepatol. (2021) 11:1–12. doi: 10.1016/j.jcmgh.2020.07.005
153. Liu Y, Zhang H, Zhang T, Yuan M, Du C, Zeng P, et al. Effects of tocilizumab therapy on circulating B cells and T helper cells in patients with neuromyelitis optica spectrum disorder. Front Immunol. (2021) 12:703931. doi: 10.3389/fimmu.2021.703931
154. Schreiber S, Aden K, Bernardes JP, Conrad C, Tran F, Hoper H, et al. Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology. (2021) 160:2354–66. doi: 10.1053/j.gastro.2021.02.062
156. Magnusson MK, Dahlen R, Strid H, Isaksson S, Simren M, Lasson A, et al. CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcerative colitis. United Eur Gastroenterol J. (2013) 1:467–76. doi: 10.1177/2050640613502962
157. Billiet T, Cleynen I, Ballet V, Claes K, Princen F, Singh S, et al. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn’s disease. Scand J Gastroenterol. (2017) 52:1086–92. doi: 10.1080/00365521.2017.1339825
158. Dai B, Hackney JA, Ichikawa R, Nguyen A, Elstrott J, Orozco LD, et al. Dual targeting of lymphocyte homing and retention through alpha4beta7 and alphaEbeta7 inhibition in inflammatory bowel disease. Cell Rep Med. (2021) 2:100381. doi: 10.1016/j.xcrm.2021.100381
159. Stienne C, Virgen-Slane R, Elmen L, Veny M, Huang S, Nguyen J, et al. Btla signaling in conventional and regulatory lymphocytes coordinately tempers humoral immunity in the intestinal mucosa. Cell Rep. (2022) 38:110553. doi: 10.1016/j.celrep.2022.110553
160. Soler D, Chapman T, Yang L, Wyant T, Egan R, and Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. (2009) 330:864–75. doi: 10.1124/jpet.109.153973
161. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. (2013) 369:699–710. doi: 10.1056/NEJMoa1215734
162. Bei Y, Chen X, Xu Q, Lv J, Hu J, and Yang S. Apatinib weakens resistance of gastric cancer cells to paclitaxel by suppressing JAK/STAT3 signaling pathway. Drug Dev Res. (2022) 83:379–88. doi: 10.1002/ddr.21867
163. Rosen H. The role of small molecule inhibition of leukocyte trafficking in inflammatory bowel disease. Gastroenterol Hepatol (N Y). (2021) 17:175–77.
164. Liu X, Zhao H, Wang H, Ge W, Zhong Y, Long J, et al. Regulatory effect of sishen pill on tfh cells in mice with experimental colitis. Front Physiol. (2020) 11:589. doi: 10.3389/fphys.2020.00589
165. Li Q, Zheng S, Niu K, Qiao Y, Liu Y, Zhang Y, et al. Paeoniflorin improves ulcerative colitis via regulation of PI3K−AKT based on network pharmacology analysis. Exp Ther Med. (2024) 27:125. doi: 10.3892/etm.2024.12414
166. Dang W, Li H, Jiang B, Nandakumar KS, Liu K, Liu L, et al. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway. Phytomedicine. (2019) 62:152965. doi: 10.1016/j.phymed.2019.152965
167. Xiang P, Zhang Y, Qu X, Chen Y, Xu Y, Li X, et al. Xiehuo Xiaoying decoction inhibits Tfh cell expansion and promotes Tfr cell amplification to ameliorate Graves’ disease. J Ethnopharmacol. (2023) 301:115826. doi: 10.1016/j.jep.2022.115826
168. Qin G, Lu P, Peng L, and Jiang W. Ginsenoside rb1 inhibits cardiomyocyte autophagy via PI3K/akt/mTOR signaling pathway and reduces myocardial ischemia/reperfusion injury. Am J Chin Med. (2021) 49:1913–27. doi: 10.1142/S0192415X21500907
169. Qu L, Liu Y, Deng J, Ma X, and Fan D. Ginsenoside Rk3 is a novel PI3K/AKT-targeting therapeutics agent that regulates autophagy and apoptosis in hepatocellular carcinoma. J Pharm Anal. (2023) 13:463–82. doi: 10.1016/j.jpha.2023.03.006
170. Zhao B, Liu Y, Gao X, Zhai H, Guo J, and Wang X. Effects of ginsenoside Rg1 on the expression of toll-like receptor 3, 4 and their signalling transduction factors in the NG108–15 murine neuroglial cell line. Molecules. (2014) 19:16925–36. doi: 10.3390/molecules191016925
171. Li Y, Shen L, and Luo H. Luteolin ameliorates dextran sulfate sodium-induced colitis in mice possibly through activation of the Nrf2 signaling pathway. Int Immunopharmacol. (2016) 40:24–31. doi: 10.1016/j.intimp.2016.08.020
172. Balan S and Bhardwaj N. Cross-presentation of tumor antigens is ruled by synaptic transfer of vesicles among dendritic cell subsets. Cancer Cell. (2020) 37:751–53. doi: 10.1016/j.ccell.2020.05.013
173. Luri-Rey C, Teijeira Á, Wculek SK, de Andrea C, Herrero C, Lopez-Janeiro A, et al. Cross-priming in cancer immunology and immunotherapy. Nat Rev Cancer. (2025) 25:249–73. doi: 10.1038/s41568-024-00785-5
174. Hubert M, Gobbini E, Couillault C, Manh TV, Doffin A, Berthet J, et al. IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. Sci Immunol. (2020) 5:eaav3942. doi: 10.1126/sciimmunol.aav3942
175. Boltjes A, Samat AAK, Plantinga M, Mokry M, Castelijns B, Swart JF, et al. Conventional dendritic cells type 1 are strongly enriched, quiescent and relatively tolerogenic in local inflammatory arthritis. Front Immunol. (2023) 13:1101999. doi: 10.3389/fimmu.2022.1101999
176. Mattiuz R, Brousse C, Ambrosini M, Cancel J, Bessou G, Mussard J, et al. Type 1 conventional dendritic cells and interferons are required for spontaneous CD4(+) and CD8(+) T-cell protective responses to breast cancer. Clin Transl Immunol. (2021) 10:e1305. doi: 10.1002/cti2.1305
177. Garcias López A, Bekiaris V, Müller Luda K, Hütter J, Ulmert I, Getachew Muleta K, et al. Migration of murine intestinal dendritic cell subsets upon intrinsic and extrinsic TLR3 stimulation. Eur J Immunol. (2020) 50:1525–36. doi: 10.1002/eji.201948497
178. León B. Type 2 conventional dendritic cell functional heterogeneity: ontogenically committed or environmentally plastic? Trends Immunol. (2025) 46:104–20. doi: 10.1016/j.it.2024.12.005
179. Hatipoglu I, Ainsua-Enrich E, Kadel S, Turner S, Singh S, and Kovats S. IRF4-regulated transcriptional and functional heterogeneity of lung-resident CD11b+ cDC2 subsets during influenza virus infection. J Immunol (Baltimore Md.: 1950). (2025) 214:1032–45. doi: 10.1093/jimmun/vkaf060
180. Guo C and Chi H. Immunometabolism of dendritic cells in health and disease. Adv Immunol. (2023) 160:83–116. doi: 10.1016/bs.ai.2023.10.002
181. Saadeh D, Kurban M, and Abbas O. Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases. Exp Dermatol. (2016) 25:415–21. doi: 10.1111/exd.12957
182. Conrad C, Meller S, and Gilliet M. Plasmacytoid dendritic cells in the skin: to sense or not to sense nucleic acids. Semin Immunol. (2009) 21:101–09. doi: 10.1016/j.smim.2009.01.004
183. Psarras A, Antanaviciute A, Alase A, Carr I, Wittmann M, Emery P, et al. TNF-α Regulates human plasmacytoid dendritic cells by suppressing IFN-α Production and enhancing T cell activation. J Immunol (Baltimore Md.: 1950). (2021) 206:785–96. doi: 10.4049/jimmunol.1901358
184. Lombardi VC and Khaiboullina SF. Plasmacytoid dendritic cells of the gut: relevance to immunity and pathology. Clin Immunol (Orlando Fla.). (2014) 153:165–77. doi: 10.1016/j.clim.2014.04.007
185. Shantsila E, Wrigley B, Tapp L, Apostolakis S, Montoro-Garcia S, Drayson MT, et al. Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. J Thromb Haemostasis: JTH. (2011) 9:1056–66. doi: 10.1111/j.1538-7836.2011.04244.x
186. Domínguez PM and Ardavín C. Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol Rev. (2010) 234:90–104. doi: 10.1111/j.0105-2896.2009.00876.x
187. Barrientos L, Bignon A, Gueguen C, de Chaisemartin L, Gorges R, Sandré C, et al. Neutrophil extracellular traps downregulate lipopolysaccharide-induced activation of monocyte-derived dendritic cells. J Immunol (Baltimore Md.: 1950). (2014) 193:5689–98. doi: 10.4049/jimmunol.1400586
188. Liao X, Liu J, Guo X, Meng R, Zhang W, Zhou J, et al. Origin and function of monocytes in inflammatory bowel disease. J Inflammation Res. (2024) 17:2897–914. doi: 10.2147/JIR.S450801
189. Li J, Zhou J, Huang H, Jiang J, Zhang T, and Ni C. Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target. Clin Transl Med. (2023) 13:e1199. doi: 10.1002/ctm2.1199
190. Maier B, Leader AM, Chen ST, Tung N, Chang C, LeBerichel J, et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature. (2020) 580:257–62. doi: 10.1038/s41586-020-2134-y
Keywords: cell–cell interactions, dendritic cells, immunology, inflammatory bowel disease, T follicular helper cells
Citation: Lv Y, Jin Y-L, Zhou Z, Liao J-B, Zhang Z-Q, Tang L-Y, Xie X-H, Wang S, Jin M-X and Liu H-Y (2026) The interaction between dendritic cells and T follicular helper cells drives inflammatory bowel disease: a review. Front. Immunol. 17:1725349. doi: 10.3389/fimmu.2026.1725349
Received: 15 October 2025; Accepted: 16 January 2026; Revised: 16 January 2026;
Published: 03 February 2026.
Edited by:
Michael A. Firer, Ariel University, IsraelReviewed by:
Hongxiang Sun, Shanghai Jiao Tong University, ChinaSharmina Deloer, National Institute of Allergy and Infectious Diseases (NIH), United States
Copyright © 2026 Lv, Jin, Zhou, Liao, Zhang, Tang, Xie, Wang, Jin and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Si Wang, d3N6eXkwMzI0QHllYWgubmV0; Meng-Xue Jin, NDkzMTAzNTJAcXEuY29t; Hong-Yi Liu, cmVhbGxpdWhvbmd5aUAxMjYuY29t
†These authors have contributed equally to this work and share first authorship